A Review of Clinical Studies of Pepleomycin

Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 74)


Pulmonary toxicity was less frequent in pepleomycin treatment of squamous cell carcinoma than in bleomycin treatment. The tumor-regressing effect appeared at about day 10 of pepleomycin treatment, and at about day 21 of bleomycin treatment. The cumulative dose of pepleomycin to complete remission was smaller than that of bleomycin. Pepleomycin is effective against bleomycin-sensitive malignancies: squamous cell carcinoma and Hodgkin’s disease. It is more effective than bleomycin against lymph node metastases. Pepleomycin may have a broader antitumor spectrum: prostatic carcinoma responded.


Toxicity Lymphoma Chlorine Sarcoma Bleomycin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hashimoto K, Shioda S, Amagasa T, Shimizu M, Sato O, Ito H, Fujibayashi T, Soda T (1979) Clinical experience with pepleomycin (NK631). Jpn J Antibiot 32:451–462PubMedGoogle Scholar
  2. 2.
    Hayashida K, Watanabe H, Ito M, Nakashima T, Toriya Y, Hiroto I, Jingu K, Hayabuchi N (1979) Clinical application of NK631 in the treatment of cancer of the tongue and floor of the mouth. Jpn J Antibiot 32:509–515PubMedGoogle Scholar
  3. 3.
    Ichikawa T (1976) Studies of bleomycin; discovery of its clinical effect, combination treatment with bleomycin and radiotherapy, side effects, and long-term survival. GANN Monogr Cancer 19:99–115Google Scholar
  4. 4.
    Iida T, Matsumoto K, Komiyama H, Okano H, Inaba O, Ogawa F, Takeda G, Takasu J (1978) Clinical experience with NK-631 in the case of oral cancer. Jpn J Oral Surg 24:983–992CrossRefGoogle Scholar
  5. 5.
    Ikeda S, Miyasato H, Nakayama H, Kobayashi Y, Tajima K (1979) Clinical trial of pepleomycin for the malignant skin tumors. Jpn Cancer Clin 25:677–687Google Scholar
  6. 6 a.
    Inuyama Y, Murakami Y, Kohno N, Mashino S, Asaoka K, Nakajima Y, Ozu R, Horiuchi M (1978) Clinical effect of NK-631 (pepleomycin) for head and neck cancer. Practica Otologica (Kyoto) 71:1517–1527CrossRefGoogle Scholar
  7. 7.
    Majima H, Oguro M, Takagi T (1979) Preclinical trial of NK631 of malignant lymphoma. Cancer Chemother 6:401–404Google Scholar
  8. 8.
    Matsuda A, Yoshioka O, Yamashita T, Ebihara K, Umezawa H, Takeuchi T, Miura T, Katayama K, Yokoyama M, Nagai S (1978) Fundamental and clinical studies on new bleomycin analogs. Recent Results Cancer 63:191–210Google Scholar
  9. 9.
    Miura T, Katayama K, Wada T (1979) Phase I and phase II studies of a new bleomycin (pepleomycin). Jpn J Antibiot 32:265–277PubMedGoogle Scholar
  10. 10.
    Nobe O, Kubo H, Yoshii K, Tashiro M (1979) Clinical experience with NK631 in malignant tumors of skin. Jpn J Antibiot 32:463–469PubMedGoogle Scholar
  11. 11.
    Sekiya T, Kawabe Y, Ito A, Kaneda T, Suzuki T, Shiraishi T (1979) A joint study of NK631 treatment of head and neck cancers. Cancer Chemother 6:777–784Google Scholar
  12. 12.
    Takata K, Honda T (1979) Primary effect of NK631 against head-and-neck cancers. Jpn J Antibiot 32:106–114PubMedGoogle Scholar
  13. 13.
    Tanaka W (1977) Development of new bleomycins with potential clinical utility. Jpn J Antibiot [suppl] 30:41–48Google Scholar
  14. 14.
    Ueno T, Shimizu M, Michi K, Ishibashi K, Kohama G (1973) Klinische Erfahrungen iiber die Behandlung mit Bleomycin von 551 Fallen der Mundhohlenkarzinome in Japan. Bull Tokyo Med Dent Univ 62:117–126Google Scholar
  15. 15.
    Umezawa H (1976) Bleomycin; discovery, chemistry, and action. GANN Monogr Cancer Res 19:3–36Google Scholar
  16. 16.
    Yokoyama M, Sato K, Wakui A, Saito T (1979) Phase I and phase II study of new bleomycin analogs - NK5033 and NK631. Cancer Chemother 6:749–758Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • S. Oka

There are no affiliations available

Personalised recommendations